Sumatriptan Succinate

ACCESS ALL DATA, CHEMISTRY

ACTIVE PHARMA INGREDIENTS

51 API Suppliers, 26 USDMF, 15 CEP/COS, 4 JDMF, 13 EU WC, 6 KDMF, 20 NDC API, 26 Listed Suppliers, $ API Reference Price

DEVELOPMENTS

5 Drugs in Development

5 Drugs in Development

INTERMEDIATES

5 Intermediates Suppliers

5 Intermediates Suppliers

FINISHED DOSAGE FORMULATIONS

386 FDF Dossiers, 97 FDA Orange Book, 212 Europe, 28 Canada, 15 Australia, 19 South Africa, 15 Listed Dossiers

DRUG PRODUCT COMPOSITIONS

INJECTABLE;SUBCUTANEOUS - EQ 4MG BASE/0.5ML (EQ 8MG BASE/ML), INJECTABLE;SUBCUTANEOUS - EQ 6MG BASE/0.5ML (EQ 12MG BASE/ML) **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons**, TABLET;ORAL - EQ 100MG BASE, TABLET;ORAL - EQ 25MG BASE, TABLET;ORAL - EQ 50MG BASE, SYSTEM;IONTOPHORESIS - EQ 6.5MG BASE/4HR, POWDER;NASAL - EQ 11MG BASE, SPRAY;NASAL - 20MG/SPRAY, SPRAY;NASAL - 5MG/SPRAY, TABLET;ORAL - 500MG;EQ 85MG BASE, TABLET;ORAL - 60MG;EQ 10MG BASE, INJECTABLE;SUBCUTANEOUS - EQ 4MG BASE/0.5ML (EQ 8MG BASE/ML), INJECTABLE;SUBCUTANEOUS - EQ 6MG BASE/0.5ML (EQ 12MG BASE/ML)